Get the Stockscreener App
4.16
5.32%
0.21
After Hours:
4.07
-0.09
-2.16%
Orchestra Biomed Holdings Inc stock is traded at $4.16, with a volume of 144.35K.
It is up +5.32% in the last 24 hours and down -3.70% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$3.95
Open:
$3.96
24h Volume:
144.35K
Relative Volume:
0.58
Market Cap:
$234.89M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-2.7733
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
+2.97%
1M Performance:
-3.70%
6M Performance:
+26.44%
1Y Performance:
-25.58%
1-Day Range:
$3.9178
$4.21
1-Week Range:
$3.9178
$4.3699
52-Week Range:
$2.20
$6.16
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.16 | 223.04M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17% - Yahoo Finance
Aug Setups: What is Orchestra BioMed Holdings Inc. s 5 year growth outlookWeekly Trading Summary & Intraday High Probability Setup Alerts - baoquankhu1.vn
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting - MSN
AMH Equity Ltd Buys New Position in Orchestra BioMed Holdings, Inc. $OBIO - Defense World
Orchestra BioMed (NASDAQ:OBIO) versus Prima BioMed (NASDAQ:IMMP) Critical Analysis - Defense World
Retail Trends: Does PNTG have strong fundamentalsQuarterly Trade Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Support Test: Is Orchestra BioMed Holdings Inc stock a contrarian buyQuarterly Performance Summary & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Retail Trends: Should value investors consider Orchestra BioMed Holdings Inc - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
Haemonetics (HAE) Acquisition of Vivasure Boosts Orchestra BioMed's Finances - GuruFocus
Orchestra BioMed Holdings, Inc. to Receive Proceeds from Vivasure Acquisition - TradingView
Early bet on vessel-closure patch could bring this firm $21M windfall - Stock Titan
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics - Sahm
Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts - Benzinga
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) market cap touched US$251m last week, benefiting both retail investors who own 41% as well as institutions - Sahm
Can Orchestra BioMed Holdings Inc. stock continue upward trendForecast Cut & Long-Term Growth Portfolio Plans - Улправда
Can Orchestra BioMed Holdings Inc. stock rebound after recent weakness2025 Historical Comparison & Weekly Watchlist of Top Performers - ulpravda.ru
Published on: 2026-01-09 01:26:31 - Улправда
Is Orchestra BioMed Holdings Inc. stock a dividend growth opportunityJuly 2025 Update & Daily Chart Pattern Signal Reports - ulpravda.ru
Is Orchestra BioMed Holdings Inc. stock a safe buy before earningsBreakout Watch & Daily Profit Focused Stock Screening - Улправда
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Orchestra BioMed (NASDAQ:OBIO) Shares Up 0.2% – Here’s Why - Defense World
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs - Insider Monkey
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra BioMed Grants New Hire Stock Options as Clinical Programs Advance - MSN
What drives Orchestra BioMed Holdings Inc stock priceEarnings Beat Highlights & Receive Monthly Expert Trading Blueprints - earlytimes.in
Orchestra BioMed Holdings, Inc.(NasdaqGM: OBIO) added to NASDAQ Biotechnology Index - marketscreener.com
Why Orchestra BioMed Holdings Inc. stock is in analyst buy zone2025 Top Decliners & Low Risk High Win Rate Stock Picks - Улправда
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates - MSN
Buyout Rumor: Can Orchestra BioMed Holdings Inc. stock rebound after recent weaknessPortfolio Gains Summary & Capital Protection Trade Alerts - Улправда
What dividend safety score for Orchestra BioMed Holdings Inc. stockWeekly Stock Recap & AI Based Buy/Sell Signal Reports - DonanımHaber
S P Trends: Is Orchestra BioMed Holdings Inc stock a safe buy before earningsQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - moha.gov.vn
Why Orchestra BioMed Holdings Inc. stock is favored by top institutionsRisk Management & Growth Focused Investment Plans - Улправда
Will Orchestra BioMed Holdings Inc. stock maintain growth storyDollar Strength & Verified High Yield Trade Plans - Улправда
Can Orchestra BioMed Holdings Inc. stock deliver consistent earnings growthMarket Sentiment Summary & Fast Entry Momentum Trade Alerts - Улправда
How Orchestra BioMed Holdings Inc. stock performs in high volatility marketsJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - bollywoodhelpline.com
Weekly Trades: What dividend safety score for Orchestra BioMed Holdings Inc stockPortfolio Risk Report & Long Hold Capital Preservation Tips - moha.gov.vn
Chmn Hochman Surrenders 43,638 Of Orchestra BioMed Holdings Inc [OBIO] - TradingView — Track All Markets
Orchestra BioMed Holdings, Inc. (OBIO) CFO has 8,670 shares withheld for taxes - Stock Titan
Orchestra BioMed (OBIO) CEO details RSU-related tax share withholding by insider - Stock Titan
Orchestra BioMed (NASDAQ:OBIO) Now Covered by Analysts at TD Cowen - Defense World
TD Cowen Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy Recommendation - Nasdaq
TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio - Investing.com Nigeria
TD Cowen Initiates Orchestra BioMed Holdings at Buy With $15 Price Target - marketscreener.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Orchestra BioMed and Medtronic Unveil Promising Hypertension Therapy Advances - Zenopa
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting - Investing News Network
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):